Study in Healthy Volunteers to Document Safety and Tolerability of Increasing Doses Pemirolast

Summary

This study is a single-centre, open-label, dose escalation , safety, tolerability and pharmacokinetics (PK) study in healthy male and female subjects. The study include a screening day and a 5-day dosing period. Subjects will be enrolled in sequential cohorts and each cohort will include 8 subjects. there will be 24 subjects total included in the study. The duration of the clinical part of the study will be approximately 2 months.

Timeline

Start

2014-10

Primary completion

2014-12

Completion

2014-12

Drugs

Indications

No indication recorded.